This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
June 19, 2013 /PRNewswire/ --
DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based,
unified eClinical® technologies and delivering related services for the clinical trials industry, today announced their partnership with SAS to provide SAS® Drug Development as an extension of the
DATATRAK ONE™ solution.
"As the innovator in cloud-based eClinical solutions,
DATATRAK brings the power of SAS Drug Development to customers with our rapid integration capabilities," stated
Laurence P. Birch,
DATATRAK's Chairman of the Board and CEO. "
DATATRAK customers already enjoy real-time access to all of their study data with our unified platform. Adding SAS Drug Development to our arsenal gives users the power of SAS Analytics across all their unified data, accelerating the drug development process through greater data visibility and real-time analysis."
Aimed at transforming clinical research processes through repeatable, sustainable improvements,
DATATRAK will work with SAS to make SAS Drug Development available in the cloud, providing data flow from
DATATRAK ONE™ into SAS Drug Development. The seamless integration is designed to streamline work processes for a company-wide implementation across the breadth of a drug development program. Intended to support Clinical Data Interchange Standards Consortium (CDISC) standards, the integrated cloud-based solution will be designed to leverage
DATATRAK's unified platform with workflows, document management, and analysis to support the current needs and future business growth of life sciences organizations.
SAS Drug Development helps organizations make informed clinical and business decisions; streamline and optimize analysis and reporting processes; assess safety and efficacy more effectively; and improve collaboration with business partners and regulatory authorities. It eases analysis and reporting for single trials as well as aggregated clinical data assets across multiple trials or therapies.